NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs NLS Pharmaceutics (NASDAQ:NLSP) and Aexon Labs expanded the DOXA platform with the AEX-6xx small-molecule series targeting arousal stability, cognition, and neuroprotection. Lead compound AEX-635 also modulates MRP1, which may aid neuroprotection and CNS bioavailability. The companies reported robust preclinical efficacy (up to 80% cataplexy reduction; >70% wakefulness increase) and plan IND-enabling studies. Financing includes ~$7M equity raised and a $25M equity line of credit, supporting operations for at least 12 months. Patents WO2024141660 and WO2024115797 are in national phases. NewCelX formation follows merger completion.

#NLSP #NLSPW NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) announced a 1-for-10 reverse share split effective in Switzerland on October 30, 2025, with Nasdaq reflecting the split at market open on October 31, 2025. Following the anticipated merger with Kadimastem, the company will change its name and trade under the new symbol NCEL. The new post‑merger CUSIP is H5835A109.The amended capital structure lists total share capital of CHF 282,908.80, a capital band allowing issuance up to 2,859,412 common shares, conditional capital provisions, and specific outstanding share counts and warrant figures after the transactions.

#NLSP #NLSPW NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) and Kadimastem (TASE: KDST) announced that all material conditions precedent for their merger have been satisfied or waived, and the merger closing is set for October 30, 2025. Nasdaq approved listing of the combined company's common shares.The combined company will be named NewCelX Ltd. and listed on the Nasdaq Capital Market under the ticker NCEL beginning October 31, 2025. Kadimastem trading on TASE will be suspended and its final delisting is scheduled for October 31, 2025.The final exchange ratio is 7.06 NLS common shares per Kadimastem share, which after a 1-for-10 reverse split of NLS shares becomes 0.706 NLS common shares per Kadimastem share. NewCelX shares are expected to be deposited to Kadimastem shareholders' accounts by the end of day November 3, 2025, with trading availability expected November 4, 2025 or soon thereafter.

#NLSP #NLSPW #KMSTF NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced an MOU between Kadimastem and TargetGene to jointly develop next-generation gene-edited cell therapies, combining Kadimastem's AstroRx and IsletRx platforms with TargetGene's DNA-guided gene-editing technology.The collaboration will operate under the combined company NewCelX upon completion of the anticipated merger between NLS and Kadimastem. The MOU frames joint R&D, technology exchange, and potential future licensing to enhance therapeutic performance, stability, and safety with a goal of scalable, curative cell-based treatments.

#NLSP #NLSPW NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 ZURICH, Oct. 23, 2025/ PRNewswire/-- NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, and Kadimastem Ltd., an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes, today announced an update regarding the proposed merger.

#NLSP #NLSPW NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

www.stocktitan.net/news/NLSP/nls-and-kadima...

84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline Shareholders approve merger creating NewCelX (NCEL), combining Kadimastem's cell therapy programs (Phase 2a ALS, diabetes) with NLS's CNS expertise. Deal gives Kadimastem 84.4% ownership.

#NLSP #NLSPW NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Game-Changing Drug Shows Success in Blocking Fentanyl's Addictive Effects Novel drug Mazindol demonstrates significant reduction in fentanyl reward behavior in preclinical study. Breakthrough findings reveal multiple mechanisms of action. Full analysis inside.

#NLSP #KMSTF #NLSPW NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Major Funding Breakthrough: NLS Pharmaceutics Raises $28M for Revolutionary ALS Treatment Development Premium-priced $2M financing plus $25M facility empowers NLS's merger with Kadimastem, accelerating ALS and diabetes therapy development. See strategic impact.

#NLSP #NLSPW NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes NLSP's AEX-2 shows efficacy for narcolepsy while expanding potential applications to neuroinflammation, ALS, and Parkinson's disease ahead of planned IND studies in 2025.

#NLSP #NLSPW NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Revolutionary Fentanyl Addiction Treatment Among 3 Major Breakthroughs from NLS Pharma NLS Pharmaceutics advances treatment frontiers with three pioneering studies: non-opioid fentanyl addiction therapy, innovative narcolepsy solution, and diabetes-related sleep disorder management.

#NLSP #NLSPW NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Game-Changing Drug Could End Fentanyl Epidemic: NLS Pharma's Bold Move NLS Pharmaceutics launches Mazindol ER preclinical program to combat fentanyl dependence amid rising overdose deaths. Patent-protected until 2038, offering new hope beyond traditional treatments.

#NLSP #KMSTF #NLSPW NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development NLS Pharmaceutics strengthens position with strategic funding, promising narcolepsy treatment results, and upcoming merger with Kadimastem. Key developments reshape company's future.

#NLSP #NLSPW NLS Pharmaceutics CEO Issues Letter to Shareholders

#news #investing #stocks

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics Secures $1M Premium-Priced Private Placement at 15% Above Market | NLSP Stock News NLS Pharmaceutics announces strategic $1M private placement with shares priced at $3.10, marking a 15% premium to market. Two-tranche offering aims to strengthen corporate initiatives.

#NLSP #NLSPW NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

#news #StockMarket #stocks

www.stocktitan.net/news/NLSP/nls-pharmaceut...